Mycobacterium abscessus (M. abscessus) pulmonary disease is a refractory chronic infectious disease. Options for treating M. abscessus pulmonary disease are limited, especially in outpatient settings. Among parenteral antibiotics against M. abscessus, intravenous amikacin (AMK) is expected to be an effective outpatient antimicrobial therapy. This study evaluated the clinical efficacy and safety of intravenous AMK therapy in outpatients with M. abscessus pulmonary disease. This retrospective chart review of cases of M. abscessus pulmonary disease evaluated patient background data, AMK dosage and duration, sputum conversion, clinical symptoms radiological findings, and adverse events. M. massiliense was excluded on the basis of multiplex PCR assay. Thirteen patients (2 men and 11 women) with M. abscessus pulmonary disease were enrolled at 2 hospitals. The median age at the initiation of intravenous AMK treatment was 65 years (range: 50–86 years). Patients received a median AMK dose of 12.5 mg/kg (range: 8.3–16.2 mg/kg) for a median duration of 4 months (range: 3–9 months). The addition of intravenous AMK led to sputum conversion in 10 of 13 patients, and 8 patients continued to have negative sputum status 1 year after treatment. Approximately half of the patients showed improvement on chest high-resolution computed tomography. There were no severe adverse events such as ototoxicity, vestibular toxicity, and renal toxicity. Thrice weekly intravenous AMK administration in outpatient settings is effective and safe for patients with M. abscessus pulmonary disease.
Aminoglycoside drugs, amikacin, streptomycin, and amikacin liposome inhalation suspension are crucial for treating refractory Mycobacterium avium-intracellulare complex pulmonary disease. In Mycobacterium tuberculosi s, cross-resistance occurs between amikacin and kanamycin, but not between amikacin and streptomycin in genetic drug susceptibility testing. However, the occurrence of cross-resistance among aminoglycosides remains unclear in M. avium-intracellulare complex. We aimed to evaluate cross-resistance among aminoglycosides to determine whether streptomycin or kanamycin remains effective after the development of amikacin resistance. This single-center retrospective study included 20 patients with amikacin-resistant M. avium-intracellulare complex harboring rrs mutations. Paired analyses of streptomycin and kanamycin minimum inhibitory concentration values before and after amikacin resistance development were performed. In addition, streptomycin– and kanamycin-resistant strains were generated in vitro and resistance-associated mutations were identified using whole-genome sequencing. No significant increase was observed in streptomycin minimum inhibitory concentration values following amikacin resistance. In contrast, kanamycin values uniformly increased to >256 µg/mL after the acquisition of amikacin resistance. Furthermore, amikacin– and kanamycin-resistant isolates shared mutations at position 1408 in the rrs gene, whereas streptomycin-resistant isolates exhibited mutations at position 20 in the rrs gene. These results suggest that amikacin and kanamycin exhibit cross-resistance in M. avium-intracellulare complex, whereas amikacin and streptomycin may not. Two cases in our cohort in which streptomycin treatment was effective after the acquisition of amikacin resistance further support these findings. In conclusion, streptomycin may be a potential therapeutic alternative for amikacin-resistant M. avium-intracellulare complex pulmonary disease. Future studies correlating streptomycin minimum inhibitory concentration values with clinical outcomes are required.
Background: Nontuberculous mycobacterial lung disease (NTMLD) is a life-threatening pulmonary infection with increasing prevalence in Japan. Asthma is a common comorbidity, but data are limited on the added illness burden of NTMLD in patients with asthma. Objective: To assess the incremental hospitalization burden of NTMLD in patients with asthma. Methods: A retrospective study was conducted with the Japan Medical Data Center claims data 2015–2020. Patients with asthma with NTMLD (cases) were matched 1:3 by age and sex to patients with asthma without NTMLD (controls). Incremental burden was assessed by comparing hospitalizations (all-cause, respiratory, and asthma) over a 1-year post-index (NTMLD diagnosis date) period with univariate and multivariate analyses adjusting for pre-index comorbidities. Results: A total of 257 cases were matched to 771 controls: mean (SD) age on index date 54 (11) years, 65% female. Bronchiectasis (11.7% vs 0.4%) and COPD (38.1% vs 9.6%) were more common in cases during the 1-year pre-index period. Univariate analyses showed greater hospitalization burden in cases vs controls (17% vs 2% had respiratory-related hospitalizations) (Figure 1A). The burden was also reflected in the multivariate analyses. Conclusion: The substantial incremental hospitalization burden associated with NTMLD in patients with asthma in Japan highlights the urgent need for appropriate management of NTMLD.
Background: Bronchiectasis (BE) is clinically diverse, and the characteristics of pulmonary exacerbations (PExs) and their associated risk factors may vary across regions and populations. A lack of large-scale data limits our understanding of these characteristics and risk factors in the Japanese BE population. Therefore, this study aimed to assess PEx risk and rate, with associated risk factors, in a real-world Japanese setting. Methods: This retrospective observational study involved people with newly diagnosed BE, identified between April 2008–June 2024, using a Japanese hospital-based claims database (Medical Data Vision Co., Ltd., Tokyo). A PEx was defined as acute respiratory infection diagnosis with concurrent antibiotic use. Covariates for PEx risk were assessed via multivariate analysis. Results: In total, 102,442 people with BE were identified (65.3% female; mean age 72.1 years). Following a new BE diagnosis, 19.3% of people were receiving long-term macrolide therapy in the first year; median time to first PEx was 322 days. Annual crude PEx rate was 0.356 (95% confidence interval: 0.354–0.358) events per person-year. Factors associated with PEx risk included a history of PExs, age, sex, BE-related diseases (primary ciliary dyskinesia, immunodeficiency, allergic bronchopulmonary aspergillosis, connective tissue disease, asthma, chronic obstructive pulmonary disease and post-infectious) and Pseudomonas aeruginosa. Conclusions: In Japan, PExs in BE occur within 1 year of diagnosis, and multiple clinical factors lead to increased PEx risk. Our findings highlight the need for early diagnosis and management strategies to mitigate PEx risk in Japanese people with BE.